Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
Praise for Becky Dorner & Associates Reducing Dementia Risk: New Research and Practical Applications Doreen Rodo, MEd, RDN, LD Kathleen Pellechia, MS, RDN, PMP Developing Coaching Skills: A Concise Introduction Brenda Richardson, MA, RDN, LDN, FAND Diet and Nutrition Care Manual 2024 Simplified Edition Course B
Bone health is also a concern with GLP-1 medications, especially for women in menopause who are already at risk for bone loss
They can both interact with insulin and medications that increase insulin release, such as sulfonylureas
For this she required specific antibodies that could home in on and bind to the peptides, even if in minute quantities
